White Paper
From Hype to Impact: Unlocking AI's Full Potential in Asia-Pacific Pharma
Sep 04, 2025

Pharmaceutical companies across Asia-Pacific are navigating rising drug development costs, increasingly complex clinical trials, and a surge in biomedical data that outpaces human capacity. Legacy systems and fragmented regulatory frameworks are slowing progress – while demand for personalized, efficient healthcare continues to grow.

This white paper explores how emerging technologies — particularly agentic AI — are reshaping the pharma value chain. From drug discovery and clinical trial optimization to regulatory affairs, manufacturing and medical affairs automation, the paper highlights how AI-driven transformation is driving measurable impact.

With a focus on Asia-Pacific pharma transformation, it outlines strategic imperatives for scaling digital capabilities, bridging the talent gap, and delivering precision medicine. Learn how leading organizations are improving supply chain resilience, enhancing HCP engagement and building future-ready operations.

Authors:

  • Devaraj Subramanian, Principal, Consulting Services, IQVIA
  • Clemence Lewden, PharmD, Consultant, Consulting Services, IQVIA

Related solutions

Contact Us